Perceptions and experiences of abemaciclib and endocrine therapy
Latest Information Update: 19 Dec 2023
At a glance
- Drugs Abemaciclib (Primary) ; Antineoplastics
- Indications Early breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms PEATY
- 14 Dec 2023 Status changed from completed to discontinued.
- 02 Sep 2023 Status changed from active, no longer recruiting to completed.
- 15 Jul 2022 Planned End Date changed from 30 Sep 2022 to 31 Aug 2023.